OncoSec Appoints Chief Clinical Development Officer

OncoSec announced the appointment of Kellie Malloy Foerter to the position of Chief Clinical Development Officer.

As Chief Clinical Development Officer, Foerter will be responsible for leading OncoSec's ongoing registration-enabled KEYNOTE-695, a global, multicenter Phase 2b, open-label trial of intratumoral delivery of TAVOTM (tavokinogene telseplasmid / plasmid IL-12) with intravenous KEYTRUDA (pembrolizumab) in patients with refractory, unresectable Stage III or Stage IV metastatic melanoma who have failed prior anti-PD-1 treatment with KEYTRUDA or OPDIVO (nivolumab). In addition to working to rapidly advance OncoSec's growing clinical pipeline, she will also be responsible for leading OncoSec's second ongoing TAVOTM / KEYTRUDA combination clinical trial in triple negative breast cancer (TNBC), KEYNOTE-890.

"I am delighted to welcome Kellie to the OncoSec team, as I know firsthand the rigor and creativity she brings with respect to clinical trial design, execution and analysis. I have no doubt she will an invaluable resource to the company as we continue to advance our clinical development pipeline, including both KEYNOTE-695 and KEYNOTE-890," said Daniel J. O'Connor, President and Chief Executive Officer of OncoSec.

With nearly three decades of experience in clinical research, Foerter joins OncoSec from Syneos Health, where she served as Executive Vice President and General Manager, Clinical Solutions. As a member of the Syneos Health Clinical executive leadership team, Foerter was responsible for the development and growth of multiple portfolios across therapeutic areas which included a strong focus on oncology and hematology trials, for the world's leading biopharmaceutical companies. Earlier, Foerter spent 20 years at inVentiv Health (previously PharmaNet) where she held multiple positions of increasing responsibility, most recently serving as Senior Vice President, Clinical Research. Prior to inVentiv, she served as Senior Project Associate, Clinical Research Associate and Clinical Studies Assistant at Covance.

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.